Oxford BioDynamics smart cancer test to launch in US

Published by

Stephen Emerson

OxfordBiodynamics

An Oxford biotech company, Oxford BioDynamics, whose product detects how well a patient's cancer treatment is performing has launched in the United States.

EpiSwitch® CiRT is a precision medicine test that predicts cancer patient's response to an Immune Checkpoint Inhibitor (ICI).

Many patients are considered for ICI immunotherapy, an alternative approach to chemotherapy or radiation, that works with a patient's immune system to fight cancer.

However, typically less than 1 in 3 patients receiving ICIs shows any benefit therefore the test will play a key role in determining if a patient should continue with treatment.

Oxford BioDynamics today announced that EpiSwitch® CiRT had achieved successful clinical validation and would launch in America.

Dr Jon Burrows, CEO of Oxford BioDynamics, said: "Oxford Biodynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT ) is a very important step forward for precision medicine. EpiSwitch® CiRT directly links clinical outcome to gene regulation and with high accuracy predicts patient response. Since one in two of us will be diagnosed with cancer in our lifetime, it is essential to develop smart testing that can rapidly predict treatment response and guide us to the most efficacious therapies and maximize benefits for patients.

"In terms of the healthcare economics, ICIs alone cost the US healthcare system $17B annually. The ability to stratify patients based on their likelihood of response will enable the system to better manage these costs while allowing us to deliver smarter, better care to patients."

Discover the best places to visit and stay in the South East of England >>

Stephen Emerson

Stephen Emerson is the Managing Editor of The Business Magazine and is responsible for the publication's print publications and online properties including the newly launched Biz News websites in Hampshire and Dorset. Stephen has been a journalist for 20 years and has worked at local, regional and national publications and led a team which made The Scotsman website one of the fastest growing news sites in the UK with over eight million monthly users. He has a keen interest in technology, property and corporate finance and telling the stories of the people behind the successful firms in these sectors.